DYN Dyne Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Dyne Therapeutics Inc reported revenue of n/a, net income of −$179M and diluted EPS of −$1.08; for the fiscal year ended December 2025 revenue was n/a.
DYN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$468M, net income −$446 (margin n/a), EPS −$3.47
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$344M, net income −$317 (margin n/a), EPS −$3.37
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$242M, net income −$236 (margin n/a), EPS −$3.95
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$171M, net income −$168 (margin n/a), EPS −$3.23
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$150M, net income −$149M (margin n/a), EPS −$2.93
DYN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$179M, EPS −$1.08
- Quarter ended Mar 31, 2026: revenue n/a, net income −$121M, EPS −$0.73
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $334M, EPS −$0.69
- Quarter ended Sep 30, 2025: revenue n/a, net income −$108M, EPS −$0.76
- Quarter ended Jun 30, 2025: revenue n/a, net income −$111M, EPS −$0.97
- Quarter ended Mar 31, 2025: revenue n/a, net income −$115M, EPS −$1.05
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $228M, EPS −$0.90
- Quarter ended Sep 30, 2024: revenue n/a, net income −$97.1M, EPS −$0.96
- Quarter ended Jun 30, 2024: revenue n/a, net income −$65.1M, EPS −$0.70
- Quarter ended Mar 31, 2024: revenue n/a, net income −$65.6M, EPS −$0.81
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $169M, EPS −$1.10
- Quarter ended Sep 30, 2023: revenue n/a, net income −$60.2M, EPS −$0.99
- Quarter ended Jun 30, 2023: revenue n/a, net income −$64.9M, EPS −$1.08
- Quarter ended Mar 31, 2023: revenue n/a, net income −$44.2M, EPS −$0.78
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $129M, EPS −$0.73
- Quarter ended Sep 30, 2022: revenue n/a, net income −$41.4M, EPS −$0.80
- Quarter ended Jun 30, 2022: revenue n/a, net income −$52.3M, EPS −$1.01
- Quarter ended Mar 31, 2022: revenue n/a, net income −$35.6M, EPS −$0.69
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$51.8M, EPS −$1.02
- Quarter ended Sep 30, 2021: revenue n/a, net income −$42.6M, EPS −$0.83
DYN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$403M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$292M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$188M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$154M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$120M, share buybacks n/a
DYN balance sheet
- Jun 30, 2026: cash $676M, total assets $994M, total liabilities $292M, shareholders' equity $702M
- Mar 31, 2026: cash $753M, total assets $1.08B, total liabilities $215M, shareholders' equity $865M
- Dec 31, 2025: cash $893M, total assets $1.19B, total liabilities $215M, shareholders' equity $972M
- Sep 30, 2025: cash $574M, total assets $867M, total liabilities $175M, shareholders' equity $692M
- Jun 30, 2025: cash $485M, total assets $729M, total liabilities $158M, shareholders' equity $571M
- Mar 31, 2025: cash $472M, total assets $721M, total liabilities $52.1M, shareholders' equity $669M
- Dec 31, 2024: cash $435M, total assets $691M, total liabilities $61.4M, shareholders' equity $630M
- Sep 30, 2024: cash $532M, total assets $769M, total liabilities $63.3M, shareholders' equity $706M
Is DYN profitable?
No. Dyne Therapeutics Inc lost $73.2M over the last four quarters.
What is DYN's EPS?
Diluted earnings per share over the last four quarters were −$3.26; −$1.08 in the latest quarter.